Copyright Reports & Markets. All rights reserved.

Global Hepatitis B Vaccine (Recombinant) Market Status and Forecast 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Hepatitis B Vaccine (Recombinant) Market Status and Forecast (2016-2027)
      • 1.3.2 Global Hepatitis B Vaccine (Recombinant) Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Hepatitis B Vaccine (Recombinant) Supply by Company

    • 2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Company
    • 2.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Company
    • 2.3 Global Hepatitis B Vaccine (Recombinant) Price by Company
    • 2.4 Hepatitis B Vaccine (Recombinant) Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Hepatitis B Vaccine (Recombinant) Market Status by Type

    • 3.1 Hepatitis B Vaccine (Recombinant) Type Introduction
      • 3.1.1 10mcg/0.5ml
      • 3.1.2 10mcg/ml
    • 3.2 Global Hepatitis B Vaccine (Recombinant) Market by Type
      • 3.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Type (2016-2021)
      • 3.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Type (2016-2021)
      • 3.2.3 Global Hepatitis B Vaccine (Recombinant) Price by Type (2016-2021)
    • 3.3 North America: by Type
    • 3.4 Europe: by Type
    • 3.5 Asia Pacific: by Type
    • 3.6 Central & South America: by Type
    • 3.7 Middle East & Africa: by Type

    4 Global and Regional Hepatitis B Vaccine (Recombinant) Market Status by Application

    • 4.1 Hepatitis B Vaccine (Recombinant) Segment by Application
      • 4.1.1 Newborn
      • 4.1.2 Adult
    • 4.2 Global Hepatitis B Vaccine (Recombinant) Market by Application
      • 4.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Application (2016-2021)
      • 4.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Application (2016-2021)
      • 4.2.3 Global Hepatitis B Vaccine (Recombinant) Price by Application (2016-2021)
    • 4.3 North America: by Application
    • 4.4 Europe: by Application
    • 4.5 Asia Pacific: by Application
    • 4.6 Central & South America: by Application
    • 4.7 Middle East & Africa: by Application

    5 Global Hepatitis B Vaccine (Recombinant) Market Status by Region

    • 5.1 Global Hepatitis B Vaccine (Recombinant) Market by Region
      • 5.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume by Region
      • 5.1.2 Global Hepatitis B Vaccine (Recombinant) Sales Value by Region
    • 5.2 North America Hepatitis B Vaccine (Recombinant) Market Status
    • 5.3 Europe Hepatitis B Vaccine (Recombinant) Market Status
    • 5.4 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Status
    • 5.5 Central & South America Hepatitis B Vaccine (Recombinant) Market Status
    • 5.6 Middle East & Africa Hepatitis B Vaccine (Recombinant) Market Status

    6 North America Hepatitis B Vaccine (Recombinant) Market Status

    • 6.1 North America Hepatitis B Vaccine (Recombinant) Market by Country
      • 6.1.1 North America Hepatitis B Vaccine (Recombinant) Sales Volume by Country (2016-2021)
      • 6.1.2 North America Hepatitis B Vaccine (Recombinant) Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Hepatitis B Vaccine (Recombinant) Market Status

    • 7.1 Europe Hepatitis B Vaccine (Recombinant) Market by Country
      • 7.1.1 Europe Hepatitis B Vaccine (Recombinant) Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Hepatitis B Vaccine (Recombinant) Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Hepatitis B Vaccine (Recombinant) Market Status

    • 8.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Market by Country
      • 8.1.1 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Hepatitis B Vaccine (Recombinant) Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Hepatitis B Vaccine (Recombinant) Market Status

    • 9.1 Central & South America Hepatitis B Vaccine (Recombinant) Market by Country
      • 9.1.1 Central & South America Hepatitis B Vaccine (Recombinant) Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Hepatitis B Vaccine (Recombinant) Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Hepatitis B Vaccine (Recombinant) Market Status

    • 10.1 Middle East & Africa Hepatitis B Vaccine (Recombinant) Market by Country
      • 10.1.1 Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Hepatitis B Vaccine (Recombinant) Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Hepatitis B Vaccine (Recombinant) Manufacturing Cost Analysis
    • 11.5 Hepatitis B Vaccine (Recombinant) Sales Channel and Distributors Analysis
      • 11.5.1 Hepatitis B Vaccine (Recombinant) Sales Channel
      • 11.5.2 Hepatitis B Vaccine (Recombinant) Distributors
    • 11.6 Hepatitis B Vaccine (Recombinant) Downstream Major Buyers

    12 Global Hepatitis B Vaccine (Recombinant) Market Forecast by Type and by Application

    • 12.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Hepatitis B Vaccine (Recombinant) Forecast by Type
      • 12.2.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume Forecast by Type
      • 12.2.2 Global Hepatitis B Vaccine (Recombinant) Sales Value Forecast by Type
      • 12.2.3 Global Hepatitis B Vaccine (Recombinant) Price Forecast by Type
    • 12.3 Global Hepatitis B Vaccine (Recombinant) Forecast by Application
      • 12.3.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume Forecast by Application
      • 12.3.2 Global Hepatitis B Vaccine (Recombinant) Sales Value Forecast by Application
      • 12.3.3 Global Hepatitis B Vaccine (Recombinant) Price Forecast by Application

    13 Global Hepatitis B Vaccine (Recombinant) Market Forecast by Region/Country

    • 13.1 Global Hepatitis B Vaccine (Recombinant) Market Forecast by Region (2022-2027)
      • 13.1.1 Global Hepatitis B Vaccine (Recombinant) Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Hepatitis B Vaccine (Recombinant) Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 GSK
      • 14.1.1 Company Information
      • 14.1.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.1.3 GSK Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Shenzhen Kangtai Biological Products
      • 14.2.1 Company Information
      • 14.2.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.2.3 Shenzhen Kangtai Biological Products Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Serum Institute
      • 14.3.1 Company Information
      • 14.3.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.3.3 Serum Institute Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Sanofi Pasteur
      • 14.4.1 Company Information
      • 14.4.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.4.3 Sanofi Pasteur Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Merck
      • 14.5.1 Company Information
      • 14.5.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.5.3 Merck Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 LG Life Sciences
      • 14.6.1 Company Information
      • 14.6.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.6.3 LG Life Sciences Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 KM Biologics
      • 14.7.1 Company Information
      • 14.7.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.7.3 KM Biologics Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Dynavax Technologies
      • 14.8.1 Company Information
      • 14.8.2 Hepatitis B Vaccine (Recombinant) Product Introduction
      • 14.8.3 Dynavax Technologies Hepatitis B Vaccine (Recombinant) Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      This report provides a comprehensive analysis of current global Hepatitis B Vaccine (Recombinant) market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario. This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Hepatitis B Vaccine (Recombinant) industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

      According to this survey, the global Hepatitis B Vaccine (Recombinant) market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million by 2027.

      Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Hepatitis B Vaccine (Recombinant) Market Status and Forecast 2021-2027 report makes a brilliant attempt to unveil key opportunities available in the global Hepatitis B Vaccine (Recombinant) market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

      The Global Hepatitis B Vaccine (Recombinant) Market has been exhibited in detail in the following chapters
      Chapter 1 displays the basic product introduction and market overview.
      Chapter 2 provides the competition landscape of global Hepatitis B Vaccine (Recombinant) industry.
      Chapter 3 provides the market analysis by type and by region
      Chapter 4 provides the market analysis by application and by region
      Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
      Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
      Chapter 12 provides the market forecast by type and by application
      Chapter 13 provides the market forecast by region
      Chapter 14 profiles global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
      Chapter 15 conclusions

      Segmented by Type
      10mcg/0.5ml
      10mcg/ml

      Segmented by Application
      Newborn
      Adult

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Serum Institute
      Sanofi Pasteur
      Merck
      LG Life Sciences
      KM Biologics
      Dynavax Technologies
      Buy now